SVB Leerink Upgrades Intersect ENT to Outperform, Raises Price Target to $23
SVB Leerink analyst Richard Newitter upgrades Intersect ENT (NASDAQ:XENT) from Market Perform to Outperform and raises the price target from $21 to $23.
Intersect ENT Insights: Return On Capital Employed
In Q1, Intersect ENT (NASDAQ:XENT) posted sales of $24.33 million. Earnings were up 7.66%, but Intersect ENT still reported an overall loss of $18.57 million. Intersect ENT collected $28.23 million in revenue during Q4, but reported earnings showed a $17.25 million loss.
Intersect ENT Receives CE Mark Approval For PROPEL Contour For Patients With Chronic Rhinosinusitis Following Frontal Sinus Surgery
Localized steroid-releasing sinus implant designed to maintain sinus opening now available in select EU countries
Intersect ENT®, Inc. (NASDAQ:XENT), a global ear, nose and throat ("ENT") medical
SVB Leerink Maintains Market Perform on Intersect ENT, Lowers Price Target to $21
SVB Leerink maintains Intersect ENT (NASDAQ:XENT) with a Market Perform and lowers the price target from $23 to $21.
Earnings Scheduled For May 10, 2021
Companies Reporting Before The Bell
• Revlon (NYSE:REV) is likely to report earnings for its first quarter.
• Bluegreen Vacations (NYSE:BVH) is expected to report earnings for its first quarter.
The Week Ahead In Biotech (May 9-15): Heron, Apellis FDA Decisions, Presentations and Earnings
Biotech stocks came under pressure in the week ended May 7 as traders digested a slew of earnings news flow and a handful of clinical trial readouts. COVID-19 vaccine stocks came under pressure following the U.S.
18 Medical Devices Stocks Moving In Wednesday’s Session
Gainers • Lianluo Smart, Inc. (NASDAQ:LLIT) stock rose 20.0% to $0.84 during Wednesday’s regular session. • Aethlon Medical,…